Latest news with #Immuron
News.com.au
17-07-2025
- Business
- News.com.au
Health Check: Immuron shares bust out for a ‘run' on strong Travelan sales
Immuron shares surge more than 30% on robust sales of the company's traveller's trots prophylactic Visionflex turns cash flow positive In Tetra-theory, this one's worth a lot more Wake up folks! It's mid-July but there's still only a trickle of June quarter reports emanating from the life sciences sector. We blame the school holidays. In the meantime companies prefer informal, unaudited updates. In this vein, Immuron (ASX:IMC) reports Travelan sales of $7.3 million for the year to June 2025, 49% higher. June quarter sales came in at $2 million, up 55%, Based on the goodness of cow's milk, Travelan is an over-the-counter immune supplement targeting gastrointestinal pathogens. Unlike most traveller's diarrhoea aids, it tackles the root of the problem rather than merely bunging it up. Travelan has been around for two decades, but the brand got a bit tired and management decided it was time to bolster promotion. In Australia, a 'clear pharmacy visibility program' helped to boost sales to $5.2 million, 40% higher. North American sales grew 76% to $2 million, with strong Amazon sales driving demand. Meanwhile medical pot supplier Little Green Pharma (ASX:LGP) reports June quarter revenue of $9.1 million, up 20%, and receipts of $12 million (50% higher). Little Green also has positive cash flow of $500,000, taking the cash balance to $2.5 million. Earlier, Little Green disclosed revenue of $36.8 million for the year to March 2025, with a $3.3 million net profit. A Visionflex turnaround is more than a remote prospect In news from the boondocks, remote healthcare outfit Visionflex (ASX:VFX) reports a June quarter revenue surge on the back of new contracts, while also turning cash flow positive. Relative to the March quarter, revenue grew 148% to $2 million. On a year-on-year basis, the turnover was 14% higher. The company managed cash flow of $300,000, compared with a $900,000 of March quarter outflows. Visionflex provides proprietary software and hardware – such as examination cameras – to remotely diagnose patients, typically in far-flung communities. During the quarter, Visionflex inked a $1 million deal with the Medibank Private (ASX:MPL) owned Amplar Health. A homecare provider, Amplar operates 30 sites. It also signed up a 'leading ASX mining company' to roll out the gear across 13 medical centres and one aircraft. Visionflex says 19% of its revenue is now recurring, which 'aligns with the company's focus on growing a more predictable, higher margin revenue base.' This quarter, the company hopes to launch a tailored homecare product. Given 900 providers service this sector with more than 2300 services, the company reckons it's tapping a rich vein. Trivarx says its depression trial is fully enrolled … TrivarX (ASX:TRI) says it has enrolled ten patients in its veterans' mental health trial and is on track to achieve its target of 30 participants. A mental health technology company, TrivarX pioneers the use of objective measures to screen for mental health conditions and detect them early. The study deploys electrocardiogram (ECG) screening to detect current major depressive episodes in veterans with suspected sleep apnoea. The trial is underway at the West Los Angeles VA Medical Center. There, participants undergo an overnight, multi-parameter sleep study and neuropsychiatric interview. The ECG algorithm extends Trivarx's lead asset, its AI-driven MEB-001 device. Trivarx expects to complete the study by mid-September. ... while Clarity also puts out the 'full house' shingle In other trial news, radiopharmaceutical developer Clarity Pharmaceuticals (ASX:CU6) says a 50 patient, phase II study of its prostate cancer imaging candidate is fully enrolled. The study evaluates Clarity's copper-isotope based agent 64Cu-SAR-bisPSMA, compared to the standard-of-care gallium-based alternative. In nuclear medicine, there are isotopes and isotopes ... Carried out at Sydney's St Vincent's Hospital, the investigator-initiated study enrols patients with low prostate-specific antigen (PSA). These patients are candidates for "curative salvage therapies". 'The high volume of patients imaged in recent months at a single site reflects the high unmet need for more effective diagnostic tools for men with rising PSA following radical prostatectomy,' Clarity executive chair Dr Alan Taylor says. The company expects trial results 'in coming months'. Tetratherix shares 'worth 58% more' Tetratherix (ASX:TTX) shares have surged a healthy 22% since the wound management company listed on June 30, but broker Morgans reckons there's another 58% of upside. The company has developed Tetramatrix, a fluid-like polymer injected into the relevant bodily area. The body temperature results in the material setting to a gum-like state that surgeons can shape to suit the purpose. The material doesn't spark a foreign body response and is reabsorbed when it has done its job. Tetratherix initially is focusing on bone regeneration, tissue spacing, and tissue healing – a US$6.8 billion market. The company expects FDA clearance for the dental product in late 2026, while the orthopedic and oncology spacing offerings should be green lit in late 2028. Morgans believes the company will be profitable in the 2027-28 year but expects a current year deficit of $10.8 million on revenue of $1 million. Morgans values the stock at $5.72 – almost double the $2.88 issue price in the $25 million raising. The firm was a joint manager for the IPO. Pacific Edge rattles the can Meanwhile, diagnostics house Pacific Edge (ASX:PEB) has launched a share purchase plan to raise up to NZ$5 million. This follows the company's June 3 conditional placement of NZ$16.1 million, NZ$1.1 million more than planned. The raising has been done at 10 NZ cents a share, an unusual 22% premium to the prevailing price. In April the company's Cxbladder test was kicked off the US Medicare coverage rota. The company says the funds partly will support operations for another 12 months without Medicare coverage, while management pursues reinstatement.
Yahoo
05-03-2025
- Health
- Yahoo
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will join Immuron's product portfolio which includes the rapidly growing Travelan® brand building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend. Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected. Some key symptoms of IBS include: abdominal pain or discomfort; stomach bloating and wind; chronic diarrhoea or constipation, or alternating between the two.1 According to available data, the IBS treatment market in Australia is estimated to be a part of the broader "Digestives & Intestinal Remedies" market, generating a revenue of around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%.2 ProIBS® is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and unsettled bowel movements (diarrhoea and/or constipation). ProIBS® contains AVH200®, derived from the plant Aloe barbadensis Miller. AVH200® has gel forming components which support the intestinal mucosal barrier. As IBS is known to affect individuals for a long period of time, it is essential to have a treatment appropriate for long-term use – as ProIBS® is. The product is safe, and no interactions with other medications are known. Science-driven innovative Calmino group AB, the developer of ProIBS®, conducted a usability study among 1,003 users. ProIBS® was helpful for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend ProIBS® to someone else. To learn more please check: Flavio Palumbo, Chief Commercial Officer said, 'Following the rapid growth of Travelan in pharmacy as the leading product for the prevention of traveller's diarrhoea3, we have identified a great opportunity with ProIBS® to further expand our digestive health portfolio by providing pharmacists a proven premium efficacy product that delivers unique benefits to their customers. With ProIBS®, we are able to provide an innovative and European certified medical device for the treatment of symptoms related to IBS. The product has been on the Swedish pharmacy market for more than a decade. Because it is backed by science and recommended by physicians and dietitians, we can promote ProIBS® with absolute confidence. We are looking forward to offering a solution that truly improves the liveability of the affected people.' Tobias Kisker, CEO and founder of Calmino group AB, is pleased to start a long and successful collaboration with Immuron. 'The Calmino team is happy to work with a well-established, experienced, and professional company like Immuron. We see Australia and New Zealand as important Asian Pacific markets with significant potential.' Otto W, Najnigier B, Stelmasiak T, Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhoea caused by enterotoxigenic Escherichia coli in volunteers. Scandinavian Journal of Gastroenterology. 2011;46:862-868. This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven LydeamoreChief Executive OfficerPh: +61 (0)3 9824 5254info@ About ImmuronImmuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. For more information visit: FORWARD-LOOKING STATEMENTS: This press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A photo accompanying this announcement is available at
